Traditional ear tube surgery alternative developer AventaMed announced that it appointed U.S.-based Keith Jensen as its new president & CEO.
The Cork, Ireland-based medtech startup said in a news release that Jensen will succeed co-founder Olive O’Driscoll in the positions as he attempts to lead the company beyond its current startup phase and into the growth and commercialization phase, having already secured more than $6.2 million (€5.2 million) in funding.
Jensen previously held leadership roles at Boston Scientific, Cortek, InaVein and was president & CEO of Vascular Insights before his most recent position as senior VP of international business for the American Heart Association. O’Driscoll is set to assume an advisory consulting position and remain on the company’s board.
AventaMed develops the Solo Tympanostomy Tube Device (Solo TTD) for the quick and simple insertion of ear tubes without general…